Summary The role of the calmodulin inhibitor trifluoperazine (TFP) in modulating the cellular levels and cytotoxicity in vitro and antitumour effects in vivo of doxorubicin (DOX), was evaluated in progressively DOX-resistant (5-to 40-fold) sublines of B16-BL6 mouse melanoma. In parental-sensitive B16-BL6 cells treated for 3 h, the IC50 of DOX was 0.1 pg ml-1, and a <2-fold enhancement in DOX cell kill in the presence of a noncytotoxic concentration of 5 pM TFP was observed. However, in the DOX-resistant sublines, the IC50 was 0.7 to 5.0 pgml -DOX in the absence of 5plM TFP and 0.3 to 0.7 pgml -DOX in the presence of 5p,M TFP. The 2-to 7.5-fold decrease in the IC50 of DOX in the presence of 5 pM TFP, was dependent on the level of DOX-resistance in the various sublines. Compared to parental-sensitive cells, a 2-fold decrease in DOX-accumulation was evident only in the 40-fold DOX-resistant subline. Further, maximal enhancement (50%) of cellular DOX accumulation in the presence of 5 pM TFP was observed only in the 40-fold resistant cells treated with 5.0,pgml-I DOX. Retention of DOX in the 40-fold resistant subline was only 20% lower than similarly treated sensitive cells, and the inclusion of TFP increased DOX retention < 10-15%. Antitumour studies in mice with experimental pulmonary metastases revealed that although DOX and DOX plus TFP had similar antitumour activity with the parental sensitive B16-BL6 cells, the combination of DOX plus TFP was significantly more effective than DOX alone with the DOX-resistant sublines. No overt toxicity was observed in normal mice treated with doses of TFP, DOX or DOX plus TFP used for in vivo chemotherapy studies. Results from this study suggest that gross cellular DOX levels do not appear to correlate with the magnitude of resistance, and the effects of TFP in modulating DOX resistance is possibly due to mechanisms other than mere alterations in cellular drug accumulation and/or retention.
The characterization of multidrug resistant cells from a pharmacokinetic, biochemical and genetic standpoint is currently an area of active investigation (Riordan & Ling, 1985) . Clinically, an understanding of the multidrug resistant phenotype is of far reaching importance in the design of novel therapeutic strategies, since the pattern of crossresistance in these cells encompasses a number of other potent antitumour drugs (Riordan & Ling, 1985) . Doxorubicin (Adriamycin), an anthracycline antitumour antibiotic is one of the most active agents used in the successful chemotherapy of leukemias and solid tumours (Carter, 1975) . The cellular effects of doxorubicin (DOX) contributing towards a cytotoxic effect are clearly multifactorial (Meyers, 1982) and studies with DOX-resistant tumour models with relatively high levels of resistance (>50-fold) have suggested that reduced accumulation and/or retention of DOX is a primary mechanism for the expression of resistance (Dano, 1976; Skovsgaard, 1978; Inaba et al., 1979) . Studies addressing the role of reduced drug retention in multidrug resistant cells have suggested that the M, 150,000-180,000 membrane glycoprotein (P-glycoprotein) is involved in the active drug extrusion process (Gerlach et al., 1986) . Although attempts to relate cellular DOX levels with cytotoxic effects have demonstrated that impaired drug uptake is a characteristic of cells with high levels of acquired DOX-resistance, there is however little correlation between DOX accumulation characteristics and degree of resistance (Ganapathi et al., 1986 (Ganapathi et al., , 1988 .
The observation that calmodulin inhibitors and calcium antagonists (Tsuruo et al., 1982; Ganapathi & Grabowski, 1983) can markedly alter the cytotoxic effects of DOX and cross-resistant drugs in cells with acquired DOX resistance, has provided circumstantial evidence for the role of calcium regulation in multidrug resistance. Early studies on modulation of cytotoxicity by these calcium modifiers suggested their role to be due to enhanced drug uptake and/or Correspondence: R. Ganapathi retention (Tsuruo et al., 1982; Ganapathi & Grabowski, 1983) . However, it has been recently demonstrated that the effects of the calmodulin inhibitor trifluoperazine (TFP) in DOX-resistant cells is possibly due to mechanism(s) other than mere modulation of gross drug levels (Ganapathi et al., 1986 (Ganapathi et al., , 1988 . Characterization of cells with acquired DOXresistance and the effects of calcium modifiers have traditionally used models with high levels of resistance, and the relevance of these findings to low levels of resistance which are likely to be encountered clinically is unknown. We have recently developed progressively DOX-resistant (5-to 40-fold) B16-BL6 mouse melanoma cells with the multidrug resistant phenotype (Ganapathi, et al., 1987) and using this model system, in the present study, we have determined the characteristics of DOX cellular pharmacokinetics (accumulation and retention) and cytotoxicity in vitro, antitumour activity of DOX in vivo, and the role of TFP in modulating these effects.
Materials and methods
The isolation of progressively DOX-resistant B16-BL6 mouse melanoma cells adapted to grow in vitro, in the presence of 0.025, 0.05, 0.1 and 0.25 jgml-1 DOX, and identified as B 16-BL6/DOXO.025, B1 6-BL6/DOXO.05, B 16-BL6/DOXO.1 and B16-BL6/DOXO.25 respectively has been previously described (Ganapathi, et al., 1987 (Ganapathi, et al., 1987) 
Doxorubicin accumulation in vitro
Log-phase cultures of parental-sensitive (BI6-BL6/S) and DOX-resistant sublines (B16-BL6/DOXO.05 and B16-BL6/ DOXO.25) harvested from monolayer cultures and resuspended at a density of I x 106 cells ml -in supplemented E-MEM with 5% FBS were treated with 0.5, 1.0 and 5.0 pg ml -1 DOX in the absence or presence of 5 pM TFP at 37°C, in a humidified 5% CO2 plus 95% air atmosphere. Duplicate samples (1 x 106 cells) removed at the end of I h and 3 h of treatment were centrifuged (lOOg) and washed twice with 7 ml of ice-cold 0.85% sodium chloride solution. After the final wash, cell pellets were mixed thoroughly in a vortex mixer with 50% ethanol-0.3 N hydrochloric acid, centrifuged at 700g, and DOX content in the supernatant determined fluorimetrically (Bachur et al., 1970; Ganapathi, et al., 1984a, b) 
Results and discussion
The effect of trifluoperazine on the cytotoxicity of doxorubicin in parental sensitive and progressively DOX-resistant sublines of B16-BL6 cells is shown in Table I . In all cell lines treated with 5 pM TFP alone, did not result in appreciable cytotoxicity compared to the untreated control, and survival was >90%. The cytotoxic effects of DOX alone were markedly dose-dependent in sensitive cells and in the presence of 5 pM TFP, <2-fold enhancement in cell kill was observed. Cell kill with DOX alone was not dose dependent up to 0.25, 0.5, 1.0 and 2.Opgml-1 DOX in the B16-BL6/ DOXO.025, B16-BL6/DOXO.05, B16-BL6/DOXO.1 and B16-BL6/DOXO.25 sublines respectively. However, with 2-to 4-fold increases in drug concentrations, DOX dose-dependent cytotoxicity was apparent. The effects of TFP in modulating DOX cytotoxicity was more apparent with the DOXresistant sublines, and compared to DOX alone, in the presence of 5 M TFP, cell kill was related to the dose of DOX over the concentration range studied. In Figure 1 (Ganapathi et al., 1987 approximately 5-, 10-, 20-, and 40-fold resistant, respectively, compared to the B16-BL6/S cells (Ganapathi, et al., 1987 Reduced accumulation of DOX in the resistant sublines compared to sensitive cells was most apparent when exposed to 5.0 jg ml -1 DOX. At 3 h with the Bl 6-BL6/DOXO.05 cells and at both I h and 3 h periods with the B16-BL6/DOXO.25 cells, cellular DOX levels were 1.3-to 2.0-fold lower than in similarly treated B16-BL6/S cells. Although TFP had little effect in enhancing DOX accumulation in B16-BL6/S cells, at 3 h with 5.0 Mg ml -1 DOX plus 5 gM TFP, cellular DOX levels in the B16-BL6/DOXO.05 and B16-BL6/DOXO.25 cells were 1.25-fold and 1.5-fold higher respectively.
Statistical analysis of the data using analysis of variance and Bonferroni t-tests (Neter & Wasserman, 1974) to identify differences in DOX accumulation and the effect of TFP in the various cell lines revealed the following: (a) in general, B16-BL6/S was not different from B16-BL6/ DOXO.05, but B16-BL6/S and B16-BL6/DOXO.05 were different from B16-BL6/DOXO.25 cells; (b) the effect of TFP on significantly (P<0.05) enhancing DOX accumulation was apparent at 3h and only in combination with 5.0 gml-1 DOX; and (c) although not statistically significant, effect of TFP on enhancing cellular DOX accumulation was dependent on the level of resistance at 3 h versus 1 h, with a tendency for a more pronounced effect in the cell lines with higher levels of resistance.
The effect of TFP on retention of DOX in B16-BL6/S and B16-BL6/DOXO.25 cells is shown in Figure 3 A minor role for TFP in competing for outward transport of DOX was apparent, since inclusion of TFP in the extracellular medium during retention increased the level of DOX retained to 50%.
The antitumour effects in vivo of TFP, DOX and DOX+TFP against experimental pulmonary metastases of B16-BL6/S, B16-BL6/DOX0.05 and B16-BL6/DOXO.25 cells is outlined in Table II . The differences in formation of experimental pulmonary metastases between sensitive and resistant sublines of B16-BL6 melanoma in control animals is in accordance with our earlier data on metastatic behaviour of this progressively DOX-resistant model system (Ganapathi, et al., 1987) . The dose and schedule of DOX and/or TFP for the in vivo studies was based on toxicity studies in naive mice demonstrating no treatment related mortality over 60 days. Further, histology of 2 M methacrylate sections of the heart stained with haematoxylin and eosin, revealed no appreciable muscle fibre damage in TFP, DOX or DOX + TFP treated mice compared to saline controls. TFP alone had no effect in reducing the tumour burden with the sensitive and DOX-resistant sublines suggesting that concentrations achieved in vivo are noncytotoxic. In mice inoculated with B16-BL6/S, DOX alone was markedly effective in reducing lung tumour burden, and the combination of DOX plus TFP was not significantly more effective than DOX alone. A 2-fold reduction in lung tumour burden with DOX alone was apparent with the B16-BL6/DOXO.05 cells, but no antitumour effects were observed with the B16-BL6/DOXO.25 subline. This difference in response could be attributed to the achievable blood levels of DOX and the 3.6 fold difference in IC50 of DOX alone between the two resistant sublines, observed in vitro ( Figure  1 ). The combination of DOX+TFP was >3-fold and >2-fold more effective than DOX alone in reduction of pulmonary metastases with the B16-BL6/DOX0.05 and B16-BL6/ DOXO.25 sublines respectively, and once again the magnitude of this response could be related to a <2-fold difference in the IC50 of DOX in the presence of TFP with these sublines (Figure 1 ). The combination of DOX plus TFP was more effective than DOX alone in the resistant sublines versus parent sensitive cells, which is in accordance with the in vitro cytotoxicity data (Table I) . Further studies on reduction in pulmonary metastases following treatment and its relationship to survival time of mice are currently ongoing.
The role of 'calmodulin inhibitors' and 'calcium antagonists' in modulating DOX-and daunorubicin-resistance in (Tsuruo et al., 1982 (Tsuruo et al., , 1983 Slater et al., 1982; Ganapathi & Grabowski, 1983 Ganapathi et al., 1984a Ganapathi et al., ,b, 1985 Kessel & Wilberding, 1985; Krishan et al., 1985; Harker et al., 1986) . The rationale for using the calcium modifiers was to enhance cellular anthracycline levels and consequently the cytotoxic effects. Although models exhibiting high levels of anthracycline resistance (Dano, 1976; Skovsgaard, 1978 , Inaba et al., 1979 and progressive resistance (Wheeler et al., 1982; Siegfried et al., 1983) demonstrate reduced drug accumulation, it is however apparent that the magnitude of reduction in cellular drug levels does not account for the degree of resistance (Ganapathi & Grabowski, 1988; Ganapathi et al., 1986) . Support for this hypothesis is apparent when comparing cytotoxicity results in Table I and the DOX accumulation data in Figure 2 . Overall, comparison of our earlier observations with a > 100-fold DOX-resistant model system (Ganapathi & Grabowski, 1983 ) and the present results on cytotoxicity ( Figure  1 and Table I ) and DOX accumulation (Figure 2 ) in progressively DOX-resistant cells suggest that the effects of TFP in modulating cytotoxicity but not accumulation is related to the degree of DOX-resistance. The antitumour studies in mice though preliminary appear promising and demonstrate that the effects of TFP in modulating DOX cytotoxicity in vitro occur in vivo as well. The magnitude of response in vivo with DOX plus TFP at high levels of resistance with the B16-BL6/DOX0.25 cells were not as encouraging as the in vitro results, and this may be related to the fact that sufficiently high cellular levels of DOX are not achieved at the maximally tolerated dose and schedule of DOX used.
In summary, results from this study demonstrate that there is little correlation between cellular accumulation of DOX and magnitude of resistance in progressively DOXresistant B16-BL6 cells. The calmodulin inhibitor TFP was appreciably more effective in enhancing cytotoxicity rather than accumulation of DOX in the progressively resistant sublines and the magnitude of TFP effects on DOX cytotoxicity was related to the level of resistance. The superior chemotherapeutic efficacy in vivo of DOX plus TFP compared to DOX alone against pulmonary metastases of DOXresistant B16-BL6 cells may be relevant to the recent demonstration (Miller et al., 1988 ) that TFP may be of therapeutic value clinically in modulating the cytotoxicity of DOX in tumours with acquired DOX-resistance.
